Quick Overview

This triple analysis focuses on cancer drug development strategies in both Leukemia and Lymphoma and by the mechanism/target/effect of Apoptosis.

Request Sample Pages or Access via 1stOncology™

You can request Free Sample Pages to Triple Analysis: Leukemia, Lymphoma and Apoptosis.

To find out more about Triple Analysis: Leukemia, Lymphoma and Apoptosis, please read the product description below.We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

Did you know that Triple Analysis: Leukemia, Lymphoma and Apoptosis is part of the 1stOncology™ platform and can be accessed at no extra cost?

1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.

This triple analysis focuses on cancer drug development strategies in both Leukemia and Lymphoma and by the mechanism/target/effect of Apoptosis. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: LeukemiaThe leukemia report part comprises defined and up to date development strategies for 313 leukemia drugs within the portfolio of 186 investigators, from Ceased to Marketed. This part extensively analyses their 204 identified drug targets, organized into 193 drug target strategies, and assesses them in eight different compound strategies and and eight subindications of leukemia.This part is based on the following publication:A Decision Support Tool for Optimizing The Leukemia Pipeline: From Research and Development to Market

Part II: LymphomaThe lymphoma report part comprises defined and up to date development strategies for 282 lymphoma drugs within the portfolio of 154 investigators, from Ceased to Marketed. This part extensively analyses their 181 identified drug targets, organized into 173 drug target strategies, and assesses them in eight different compound strategies and and five subindications of lymphoma.This part is based on the following publication:A Decision Support Tool for Optimizing The Lymphoma Pipeline: From Research and Development to Market

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Request Sample Pages or Access via 1stOncology™

You can request Free Sample Pages to Triple Analysis: Leukemia, Lymphoma and Apoptosis.To find out more about Triple Analysis: Leukemia, Lymphoma and Apoptosis, please read the product description below.We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

Did you know that Triple Analysis: Leukemia, Lymphoma and Apoptosis is part of the 1stOncology™ platform and can be accessed at no extra cost?

1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.

Or

Other selected research from the 'Triple Analysis' category:

This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Pancreatic Cancer), one mechanism/target/effect area (Protein Kinase Inhibitors) and one compound specific area (Antibodies).Learn More

Other selected research from the 'Oncology' category:

This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Pancreatic Cancer), one mechanism/target/effect area (Angiogenesis) and one compound specific area (Antibodies).Learn More